Chau T Dang MD
Assistant Professor, Medicine, Weill Cornell Medical College
500 Westchester AvenueWest Harrison, NY 10604
Overview of Dr. Dang
Dr. Chau Dang is an oncologist in West Harrison, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, NYC Health + Hospitals / Bellevue, New York-Presbyterian Hospital, Phelps Memorial Hospital Center, and Memorial Hospital for Cancer and allied Diseases. She received her medical degree from Medical University of South Carolina and has been in practice 34 years. Dr. Dang accepts several types of health insurance, listed below. She is one of 529 doctors at Memorial Sloan Kettering Cancer Center and one of 66 doctors at NYC Health + Hospitals / Bellevue who specialize in Oncology. She has more than 100 publications and over 500 citings.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 1996 - 1999
Allegheny Health Network Medical Education Consortium (AGH)Residency, Internal Medicine, 1993 - 1996
Eastern Virginia Medical SchoolInternship, Transitional Year, 1992 - 1993
Medical University of South CarolinaClass of 1992
Certifications & Licensure
FL State Medical License 2021 - Present
NJ State Medical License 2019 - 2027
NY State Medical License 1996 - 2027
PA State Medical License 1994 - 1996
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification MyMSK, Memorial Sloan Kettering, 2016
- CMS Meaningful Use Stage 1 Certification Sunrise Ambulatory Care, Allscripts, 2016
Clinical Trials
- Celecoxib and Trastuzumab in Treating Women With Metastatic Breast Cancer
- Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer Start of enrollment: 2007 Nov 02
- Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer
Publications & Presentations
PubMed
- Benralizumab for Eosinophil-Related Cutaneous Adverse Events of Anticancer Therapy: A Phase II Trial.Mario E Lacouture, Alexander Pan, Tara Maier, Anna Chen, George Dranitsaris
Clinical Cancer Research. 2026-08-03 - A Telemedicine-Supported Home-Injection Model for Patients With Breast Cancer.Charlotte D Malling, Erin M Bange, Anne S Reiner, Katherine Marcinkowski, Simone Porter
JAMA Network Open. 2026-08-03 - Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.William J Gradishar, Meena S Moran, Jame Abraham, Vandana Abramson, Rebecca Aft
Journal of the National Comprehensive Cancer Network. 2026-07-01
Journal Articles
- Left Ventricular Ejection Fraction Monitoring Adherence RatesChau T Dang, Sandra M Swain, Anne Blaes, ScienceDirect
Press Mentions
Impressive Disease Control in Metastatic Triple-Negative Breast CancerMay 14th, 2021- BERENICE: Further Evidence of Heart Safety of Dual HER2 BlockadeMay 13th, 2021
Emerging Cardio-Oncology Field Fights Heart Disease in Breast Cancer PatientsOctober 30th, 2019
Professional Memberships
- Member
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
GHI PPO
Great West PPOHumana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
